SageView Advisory Group’s Filana Therapeutics FLNA Stock Holding History

SageView Advisory Group’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$218	Buy	+110	New	+$352	﹤0.01%	2508

Other funds holding FLNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SageView Advisory Group's FLNA Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Filana Therapeutics (FLNA) in Q4 2025: 110 shares worth $218. The stake represents ﹤0.01% of the portfolio and ranks #2508 among its holdings.

107 funds tracked by Wall St. Rank hold FLNA as of Q4 2025.

SageView Advisory Group held 110 shares of Filana Therapeutics worth $218 as of Q4 2025.
Filana Therapeutics was a new SageView Advisory Group position in Q4 2025.
Filana Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2508 holding.
107 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.